Piramal Pharma to Conclude Distribution Agreement with Bayer Pharmaceuticals
Piramal Pharma Ltd 路 Others (Uncategorized) 路 02 Oct 2026, 1:40 am
Piramal Pharma to Conclude Distribution Agreement with Bayer Pharmaceuticals Piramal Pharma announced that its commercial arrangement providing sales and distribution support services to Bayer Pharmaceuticals will conclude upon natural expiry on 31st Dec'26, with no renewal beyond the current term. The company earned commission-based income under this pact, which accounts for under 5% of its consolidated revenue. Given its commission-based structure, the non-renewal is not expected to have a material impact on Piramal Pharma's profitability or overall financial position, and the company is working with Bayer to ensure an orderly operational transition.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund 路 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 路 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. 路 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. 路 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 路 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 路 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 28 Oct 2026
- Please find enclosed unaudited financial results for Q2 FY 27 路 28 Oct 2026
